Aquinnah Pharmaceuticals is harnessing the power by integrating the fields of stress granule biology, RNA binding proteins & bimolecular condensate formation to develop oral small molecule drug candidates in Neurodegenerative Diseases. Aquinnah’s therapeutics are designed to stop or even reverse diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal disease (FTD) and Alzheimer’s disease by eliminating pathologies caused by the proteins TDP-43 or tau. Aquinnah is financially backed by Pfizer, Inc., AbbVie, Inc. and Takeda Pharmaceuticals and has received numerous awards from the ALS Association, National Institutes of Health, the Alzheimer’s Association and the Rainwater Foundation.
